{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral&page=2",
    "query": {
      "intervention": "Oral",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T16:43:41.970Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01997190",
      "title": "Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Pleural Effusion",
        "Lung Cancer",
        "Mesothelioma",
        "Breast Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "AdV-tk + valacyclovir",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2013-10",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2023-08-25",
      "last_synced_at": "2026-09-13T16:43:41.970Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01997190"
    },
    {
      "nct_id": "NCT03068910",
      "title": "Hyperandrogenemia and Altered Day-night LH Pulse Patterns",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hyperandrogenism",
        "Polycystic Ovary Syndrome",
        "Puberty"
      ],
      "interventions": [
        {
          "name": "Micronized progesterone",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "FEMALE",
        "summary": "10 Years to 17 Years · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2016-07-21",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-09-13T16:43:41.970Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03068910"
    },
    {
      "nct_id": "NCT06111521",
      "title": "A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LY3537982",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 35,
      "start_date": "2023-10-27",
      "completion_date": "2024-04-01",
      "has_results": false,
      "last_update_posted_date": "2024-11-08",
      "last_synced_at": "2026-09-13T16:43:41.970Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06111521"
    },
    {
      "nct_id": "NCT01395914",
      "title": "Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cachexia",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Anamorelin HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Helsinn Therapeutics (U.S.), Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 513,
      "start_date": "2011-07",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2017-09-14",
      "last_synced_at": "2026-09-13T16:43:41.970Z",
      "location_count": 19,
      "location_summary": "Corona, California • Fountain Valley, California • Fullerton, California + 16 more",
      "locations": [
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01395914"
    },
    {
      "nct_id": "NCT07809984",
      "title": "Prevention of Oral Mucositis in Adults in With Hematologic Malignancy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Oral Mucositis"
      ],
      "interventions": [
        {
          "name": "Aloe Vera Mouthwash",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2026-10",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-13T16:43:41.970Z",
      "location_count": 3,
      "location_summary": "Oak Lawn, Illinois • Park Ridge, Illinois • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07809984"
    },
    {
      "nct_id": "NCT01147458",
      "title": "A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "PF-04191834",
          "type": "DRUG"
        },
        {
          "name": "PF-04191834 placebo",
          "type": "DRUG"
        },
        {
          "name": "Naproxen placebo",
          "type": "DRUG"
        },
        {
          "name": "Naproxen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 190,
      "start_date": "2010-07",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2013-06-06",
      "last_synced_at": "2026-09-13T16:43:41.970Z",
      "location_count": 25,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147458"
    },
    {
      "nct_id": "NCT03030248",
      "title": "Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridium Difficile Infection",
        "Hematologic Diseases",
        "Bone Marrow Transplant",
        "Oncologic Disorders"
      ],
      "interventions": [
        {
          "name": "Vancomycin Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2018-06-01",
      "completion_date": "2020-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-09-13T16:43:41.970Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03030248"
    },
    {
      "nct_id": "NCT03415126",
      "title": "A Study of ASN007 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Malignancy",
        "Neoplasia",
        "Neoplasm",
        "Neoplasm Metastasis",
        "Colon Cancer",
        "Colonic Neoplasms",
        "Colon Cancer Liver Metastasis",
        "Metastatic Cancer",
        "Metastatic Melanoma",
        "Metastatic Colon Cancer",
        "Metastatic Lung Cancer",
        "Non Small Cell Lung Cancer Metastatic",
        "Pancreatic Cancer",
        "Pancreas Cancer",
        "Pancreas Adenocarcinoma",
        "Pancreas Neoplasm",
        "Metastatic Nonsmall Cell Lung Cancer",
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "ASN007: ascending doses",
          "type": "DRUG"
        },
        {
          "name": "ASN007 RD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Asana BioSciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2018-01-19",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-07-09",
      "last_synced_at": "2026-09-13T16:43:41.970Z",
      "location_count": 5,
      "location_summary": "Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03415126"
    },
    {
      "nct_id": "NCT01372826",
      "title": "Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "NKTR118 Group1",
          "type": "DRUG"
        },
        {
          "name": "NKTR118 Group 2",
          "type": "DRUG"
        },
        {
          "name": "NKTR118 Group3",
          "type": "DRUG"
        },
        {
          "name": "NKTR118",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 32,
      "start_date": "2011-06",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-09-13T16:43:41.970Z",
      "location_count": 3,
      "location_summary": "Anaheim, California • Orlando, Florida • Overland Park, Kansas",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01372826"
    },
    {
      "nct_id": "NCT06496568",
      "title": "A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "PIK3CA-Mutated Cancers"
      ],
      "interventions": [
        {
          "name": "Inavolisib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-12-11",
      "completion_date": "2027-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-13T16:43:41.970Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06496568"
    }
  ]
}